Anima Biotech - mRNA Lightning™ Platform
Visualize and Decode
mRNA Biology
Anima Biotech is a recognized leader in small molecule mRNA drugs. Backed by our strategic collaborations with Lilly, Takeda and Abbvie, our mRNA lightning™ platform is bringing AI to mRNA biology. With our proprietary visualization technologies, we have generated over 2 billion images of the mRNA life cycle in cells and trained disease-specific image neural networks that visually recognize the mRNA regulatory pathways underlying disease mechanisms. With our tera-scale platform, we conduct millions of massively parallel automated biology experiments, screening for active molecules that revert the images of diseased cells back to a healthy phenotype. Our MOAi technology uses mRNA biology knowledge graph, LLM and the Lightning co-pilot to identify their mechanisms of actions and molecular targets. We advance a broad pipeline across therapeutic areas in immunology, oncology and neuroscience, and partner with Pharma in the discovery of mRNA drugs, targets and vaccines.
mRNA Lightning™ Applications
Our mRNA Lightning platform visualizes and decodes mRNA biology across multiple applications. In target discovery, our approach enables the identification of novel targets underlying disease biology. We then proceed to identify small molecule mRNA drugs that directly impact the disease phenotype, as they are visually modifying the images of mRNA biology in diseased cells to look like healthy ones. mRNA Lightning's unique ability to visualize mRNA biology in cells makes it a powerful platform for many additional applications in mRNA biology, such as the optimization of mRNA vaccines, siRNA, or ASO drugs.
2 Billion mRNA Biology Images
The world's largest dataset of mRNA biology visualizations
In over a decade of working across dozens of drug discovery programs in our pipeline and with partners, we have generated a vast amount of proprietary mRNA biology data that is driving our platform's applications. We use AI to analyze and process over 2 billion images of mRNA biology and leverage our mRNA knowledge graph and large language models for querying this large-scale data. Bringing AI to mRNA biology, our platform makes the decoding of complex biology possible.
Visualizing and Decoding mRNA biology
curated publications
experimental results
technologies
High-Content High-Throughput Platform
Our mRNA biology lab is a massively parallel, fully automated lab with robotics and high-end microscopy, incorporating our imaging and mRNA biology assays in high-content, high-throughput screening. The lab is running multiple screening lines in parallel, using screen-to-cloud architecture to process data at ultra-high speeds. Millions of mRNA biology images are uploaded to the cloud for analysis by the mRNA image network, our mRNA biology LLM, MOAi technology, and the Lightning co-pilot.
AI Co-pilot
Image Network
Biology LLM
mRNA biology lab
mRNA Biology Pathway Visualizers
PathwayLight technology enables the visualization of dozens of mRNA regulatory pathways such as splicing, localization, modification, or decay/stability. Each of these visualizers is built as a high-content screening assay with the images acting as visual readouts of pathway biology.
-
Transcription
-
Splicing
-
Alternative splicing
-
Capping
-
Polyadenylation
-
Modification
-
Nuclear Export
-
Transport
-
Localization
-
Stability
-
Decay
-
Translation
Disease Signature
The mRNA image neural network identifies mRNA regulatory pathways that differentiate healthy and diseased cells, identifying the mRNA biology signature of a specific disease and forming the foundation for our target and drug discovery approaches.
The mRNA Biology Community
As the leader in mRNA biology research with a platform that spans multiple applications, Anima has initiated the LightON mRNA Community, which now includes over 5,000 mRNA biology experts and enthusiasts from industry and the academy.
Our running webinar series provides free valuable educational insights, covering the applications of researching mRNA biology for target discovery, drug discovery, and optimization of mRNA vaccines and RNA-based drugs.
mRNA Biology Modulators Pipeline
Anima's wholly-owned pipeline of mRNA biology modulators is in Immunology (Lung fibrosis candidate advancing in preclinical stage), in Oncology (Solid tumors lead compounds entering preclinical stage and additional programs against Lymphoma and Neuroblastoma), in Neuroscience (Alzheimer's disease and Pain). In addition to our own pipeline, we established strategic collaborations with Pharma in partnered programs including our collaborations with Lilly, Takeda Pharmaceuticals, and Abbvie.
| Indication | Target | Discovery |
Optimization |
Preclinical |
|
|---|---|---|---|---|---|
Immunology |
|||||
| Lung fibrosis | 1 | ||||
| Multiple fibrosis | 2 | ||||
| Multiple fibrosis | 3 | ||||
| Undisclosed |  |
4 | |||
Oncology |
|||||
| Solid tumors | 5 | ||||
| Solid tumors | 6 | ||||
| Leukemia | 7 | ||||
| Neuroblastoma | 8 | ||||
| Solid tumors | 9 | ||||
| Undisclosed | |
10 | |||
| Undisclosed | 11 | ||||
Neuroscience |
|||||
| Alzheimer | 12 | ||||
| Pain | 13 | ||||
| Undisclosed | 14 | ||||
| Undisclosed |  |
15 | |||
| Undisclosed | 16 | ||||
| Huntington | 17 | ||||
| Undisclosed |  |
18 | |||
| Undisclosed | 19 | ||||
| Undisclosed | 20 | ||||
| Area | Indication | Target | Discovery |
Optimization |
Preclinical |
||
|---|---|---|---|---|---|---|---|
| Immunology | Lung fibrosis | 1 | |||||
| Multiple fibrosis | 2 | ||||||
| Multiple fibrosis | 3 | ||||||
| Undisclosed | |
4 | |||||
| Oncology | Solid tumors | 5 | |||||
| Solid tumors | 6 | ||||||
| Leukemia | 7 | ||||||
| Neuroblastoma | 8 | ||||||
| Solid tumors | 9 | ||||||
| Undisclosed | |
10 | |||||
| Undisclosed | 11 | ||||||
| Neuroscience | Alzheimer | 12 | |||||
| Pain | 13 | ||||||
| Undisclosed | 14 | ||||||
| Undisclosed | |
15 | |||||
| Undisclosed | 16 | ||||||
| Huntington | 17 | ||||||
| Undisclosed | |
18 | |||||
| Undisclosed | 19 | ||||||
| Undisclosed | 20 | ||||||
17 Scientific Collaborations
16 Peer Reviewed Publications
-
Virtual plates: Getting the best out of high content screens
SLAS Discov (2023) Nov 29:S2472-5552(23) -
Measuring mRNA translation in neuronal processes and somata by tRNA-FRET
Nucleic Acids Res. 2020 ;46(6):e32 -
A heterogeneous tRNA granule structure exhibiting rapid, bi-directional neuritictransport
Eur J Cell Biol (2018) ; 97 : 168-179. -
Monitoring protein synthesis in single live cancer cells
Integr Biol (2016); 8 :645-53
Coverage
News & Events
-
RNA Leaders Europe Congress 2024
When:
Where: Basel, SwitzerlandAnima’s Vice President of Business Development, Gal Gur, Ph.D., will participate in the upcoming congress during in two roundtable sessions, both focused on the topic of, “Target selection – lessons learned from small molecules RNA Biology,” to discuss her learnings from working on target selection in...
-
Anima Biotech Announces Preclinical Data of Candidate in Idiopathic Pulmonary Fibrosis
When:
Anima Biotech, the Tech.Bio leader bringing AI to mRNA biology, announced today positive preclinical data of its lung fibrosis candidate. This drug operates through a novel mRNA biology mechanism of action, opening new avenues for treating Idiopathic Pulmonary Fibrosis (IPF) patients.
Utilizing its mRNA Lightning™... -
6th Annual RNA-Targeted Drug Discovery and Development Summit
When:
Where: Boston, MAAnima Biotech will participate in the 6th Annual RNA-Targeted Drug Discovery and Development Summit taking place in Boston, MA from December 12-14, 2024. Our Vice President of Business Development, Gal Gur, Ph.D., will participate on a panel titled, “Overcoming Key Challenges to Improve Drug Design & Discovery...